Evolus Downgraded to Hold by Needham Analyst: Price Target Remains at $22.00 USD

Evolus Inc (EOLS) has received a downgrade from Needham analyst Serge Belanger from 'Buy' to 'Hold' while maintaining a $22.00 USD price target. The adjustment reflects a change in the analyst's perspective on the company's potential, but the valuation is maintained. Historical ratings and forecasts indicate a positive outlook for Evolus, with an average target price of $19.83 and a high estimate of $22.00. The estimated GF Value for Evolus in one year is $21.82, suggesting a potential upside of 144.89% from the current price.

Evolus Inc (EOLS), a performance beauty company, has received a downgrade from Needham analyst Serge Belanger from 'Buy' to 'Hold', while maintaining a $22.00 USD price target. The adjustment reflects a change in the analyst's perspective on the company's potential, but the valuation is maintained. Historical ratings and forecasts indicate a positive outlook for Evolus, with an average target price of $19.83 and a high estimate of $22.00. The estimated GF Value for Evolus in one year is $21.82, suggesting a potential upside of 144.89% from the current price [1].

Evolus Inc, headquartered in Newport Beach, California, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults, and Evolysse, a collection of injectable hyaluronic acid gels [2].

The company recently reported a quarterly loss of $0.24 per share, which was a significant surprise compared to the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.07 per share a year ago. Over the last four quarters, Evolus has not been able to surpass consensus EPS estimates [1].

The sustainability of the stock's immediate price movement will depend on management's commentary on the earnings call. Evolus shares have lost about 17.5% since the beginning of the year versus the S&P 500's gain of 7.6%. The company posted revenues of $69.39 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 16.33% [1].

Evolus' performance has been underwhelming, and the company has not been able to beat consensus revenue estimates over the last four quarters. The Zacks Rank for Evolus is #3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [1].

The outlook for the industry can also impact the performance of the stock. The Zacks Industry Rank for Medical - Products is currently in the bottom 38% of the 250 plus Zacks industries. SurModics (SRDX), another company in the same industry, is expected to post a quarterly loss of $0.21 per share, representing a year-over-year change of +22.2% [1].

Investors should keep an eye on Evolus' earnings outlook and estimate revisions. The current consensus EPS estimate for the coming quarter is -$0.02 on $86.76 million in revenues, and for the current fiscal year, it is -$0.11 on $350.01 million in revenues [1].

References:
[1] https://www.nasdaq.com/articles/evolus-inc-eols-reports-q2-loss-lags-revenue-estimates
[2] https://finance.yahoo.com/quote/EOLS/